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Introduction: To evaluate efficacy and secondary resectability in patients with locally advanced pancreatic cancer
(LAPC) treated with neoadjuvant chemoradiotherapy (CRT).
Patients and methods: A total of 215 patients with locally advanced pancreatic cancer were treated with
chemoradiation at a single institution. Radiotherapy was delivered with a median dose of 52.2 Gy in single
fractions of 1.8 Gy. Chemotherapy was applied concomitantly as gemcitabine (GEM) at a dose of 300 mg/m
2
weekly, followed by adjuvant cycles of full-dose GEM (1000 mg/m
2). After neoadjuvant CRT restaging was done to
evaluate secondary resectability. Overall and disease-free survival were calculated and prognostic factors were
estimated.
Results: After CRT a total of 26% of all patients with primary unresectable LAPC were chosen to undergo
secondary resection. Tumour free resection margins could be achieved in 39.2% (R0-resection), R1-resections were
seen in 41.2%, residual macroscopic tumour in 11.8% (R2) and in 7.8% resection were classified as Rx. Patients with
complete resection after CRT showed a significantly increased median overall survival (OS) with 22.1 compared to
11.9 months in non-resected patients. Median OS and disease-free survival (DFS) of all patients were 12.3 and 8.1
months respectively. In most cases the first site of disease progression was systemic with hepatic (52%) and
peritoneal (36%) metastases.
Discussion: A high percentage of patients with locally advanced pancreatic cancer can undergo secondary
resection after gemcitabine-based chemoradiation and has a relative long-term prognosis after complete resection.
Introduction
To date, the minority of patients with pancreatic
tumours is amenable to curative resection. Facing an
increasing incidence in pancreatic cancer, optimization
of treatment with extended disease-free and overall sur-
vival (DFS and OS) while preserving quality of life is a
special focus in patients with locally advanced pancreatic
cancer (LAPC).
In 80-90% of all patients diagnosed with pancreatic
cancer, locally advanced disease associated with regional
lymph node invasion or systematically disseminated dis-
ease can be observed [1-5]. Therefore, only about 10-
20% of all tumours can be primarily resected, and even
in resected patients only about 20% of all patients sur-
vive for more than 5 years [6-10]. Since the strongest
prognostic factor for outcome is the extent of resection,
and tumour-free (R0) resection is the ultimate goal, stra-
tegies to increase resectability and to enable the surgeon
to achieve complete resections are of special interest
[11,12]. Neoadjuvant radiation combined with che-
motherapy has been proven to be effective and to lead
to substantial downstaging prior to surgery, associated
with improved outcome, for several tumour entities
[4,5,13-17]. For pancreatic cancer, similar approaches
have been introduced, with controversial clinical data.
Two recent meta-analyses have shown substantial bene-
fit of preoperative chemoradiation in locally advanced
pancreatic cancer [18,19]. For CRT there is no
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fluorouracil (5-FU) in pancreatic carcinoma. GEM is a
nucleoside analogue which exerts its anti-tumour activ-
i t yb yi n c o r p o r a t i o no fam e t a b o l i t ei n t oD N A - s t r a n d s
during replication and thus leading to a growth inhibi-
tion of the cell [20]. Furthermore GEM is a potent
radiosensitizer with impact on cell cycle effects and cell
death pathways [21].
The present study, evaluates outcome and rate of sec-
ondary resectability in a large group of patients treated




From 2001 to 2010 a total of 215 consecutive patients
with locally advanced and inoperable pancreatic cancer
were treated with chemoradiotherapy (CRT) including
radiotherapy and concurrent chemotherapy with GEM.
All patients were evaluated in an interdisciplinary setting
including all relevant specialties.
Seventeen patients were excluded from analysis
because of the following reasons: recurrent pancreatic
carcinoma, newly detected distant metastasis during
initiation of CRT, treatment only with intraoperative
radiotherapy in our institution (combined CRT in
another facility), non-suitability for surgery because of
age (n = 1) or liver cirrhosis (n = 1). The median age
was 67 years (range 42-93 years) and 110 patients were
male and 88 female. Patient characteristics are shown in
Table 1.
Combined CRT was indicated in cases of locally
advanced non-metastasized pancreatic carcinoma. Before
therapy was initiated a biopsy of the tumor was per-
formed with the histology of ductal adenocarcinoma. If
a biopsy was not possible or the acquired specimen was
too small for pathological assessment, elevated levels of
CA-19-9 and a CT scan clearly showing a pancreatic
mass were accepted as a proof of pancreatic cancer. In
some patients without histological confirmation material
obtained during subsequent resection after CRT con-
firmed the diagnosis of pancreatic cancer. Criteria for
non-resectability were a more than 180 degrees encase-
ment of the superior mesenteric artery, infiltration of
the celiac trunk, an unreconstructible occlusion of the
superior mesenteric vein or portal vein, aortic invasion
or a surrounding tumour of parts of the abdominal
aorta.
Radiation and chemotherapy
For treatment planning, CT imaging was performed
according to an in-house standard protocol in supine
position. 3-D treatment planning was performed in all
patients. GEM i.v. was applied weekly during radiation
at a dose of 300 mg/m
2. After completion of chemora-
diation, adjuvant cycles of GEM were applied with full
dose levels of 1000 mg/m
2 until resectability or disease
progression. Two patients received 5-fluorouracil addi-
tionally and 1 patient received capecitabine during CRT
together with GEM. Before application of GEM, blood
values were examined; leucocytes were required to
exceed 3.000/μl and platelets to exceed 100.000/μl.
Furthermore, physical examination was performed to
exclude any evidence of severe infection. During com-
bined CRT and during the adjuvant cycles blood cell
Table 1 Patient and treatment details
Number (%)
(n = 215)




Age (median, range) 67 (42 - 93)
Tumour Location
(tumours may involve more than 1 region)
Head 114 (58%)
Head and Body 27 (14%)
Body 36 (18%)
Body and Tail 3 (2%)
Tail 6 (3%)
Head, Body and Tail 5 (3%)
No information 7 (4%)
Radiotherapy
< 50 Gy 30 (16%)
≥ 50 Gy 160 (84%)
Median Dose (range) 52.2 Gy (39.6 - 54.4 Gy)
Previous Chemotherapy
All 23 (12%)
Gemcitabine mono 11 (6%)
Gemcitabine-containing regimen 8 (5%)
Concomitant Chemotherapy
All 198
Gemcitabine-containing regimen 198 (100%)
Gemcitabine mono 194 (97.5%)
Gemcitabine + 5-FU or Capecitabine 3 (1.5%)
Gemcitabine + Cisplatin 1 (0.5%)
IORT After Tumor Resection 26 (51%) (n = 51)
IORT - Doses (n = 26)
10 Gy 1 (4%)
12 Gy 4 (15%)
15 Gy 21 (81%)
IORT, intra-operative radiotherapy
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weekly.
Intraoperative radiotherapy was applied in 26 patients
with a median dose of 15 Gy (range 10-15 Gy) (Table 1).
Assessment of response
Two to six weeks after completion of chemoradiation
and after 1 cycle of full-dose GEM evaluation of treat-
ment response and assessment of resectability was per-
formed. In most patients contrast-enhanced computed
tomography (CT) or magnetic resonance imaging (MRI)
was conducted. Seven patients underwent surgery with-
out previous diagnostic restaging. Decision on surgical
resection was made in the interdisciplinary setting.
In patients not classified as candidates for secondary
surgical resection, but presenting with stable disease,
GEM full dose was continued, and re-assessment of the
tumour status was performed continuously.
Surgery and pathological workup
After response to CRT on radiographic imaging or in
cases where response was suspected to have occurred
without evident confirmation on imaging, surgery or
explorative interventions aiming at resection were per-
formed in our institution. Resected specimen were pre-
pared and diagnosed as primarily described [22].
Follow-up and statistics
All patients were followed on a regular basis after CRT
and response was classified according to the RECIST
criteria (Response Evaluation Criteria In Solid Tumours,
version 1.1, 2009). Besides the application of adjuvant
cycles of full-dose GEM, regular imaging examinations
included contrast-enhanced CT- or MR-imaging of the
abdomen and analysis of tumour markers.
Overall survival was calculated from the first day of
irradiation until death. Disease-free survival (DFS) was
calculated from the first day of radiotherapy until docu-
mented progression of disease (local or distant
metastasis). The log-rank test was implemented to com-
pare survival curves evaluating the association between
clinical variables of interest and survival. All calculations
were performed using the statistical software program
SPSS 18.0 for Windows (Chicago, Illinois, US).
The study is in compliance with the Helsinki Declara-
tion (Sixth Revision, 2008). Furthermore our study was
approved by the Institutional Review Board/the indepen-
dent Ethics Committee of the Medical Faculty Heidel-
berg (ref. nr.: S-483/2011).
Results
Response and resectability after chemoradiation
Response assessment after CRT and adjuvant cycles of
full-dose GEM was performed to re-evaluate resectabil-
ity. According to RECIST criteria, at first follow-up, 11%
of the patients had progressive disease (PD). In 9% a
partial remission (PR) was observed, and 80% of the
patients presented with stable disease (SD). Seven
patients did not receive another CT or MRI scan before
surgery and were considered for resection or at least
explorative laparotomy directly after CRT. Figure 1
depicts a partial remission of a large inoperable tumour
due to CRT with GEM.
Secondary espectability was decided in 51 cases (26%),
and in an additional 53 patients (28%) surgery was
scheduled but was performed as explorative laparotomy
(28%) because of intraoperative non-resectability of the
primary tumour (n = 30 (58%)) or new diagnosis of
metastasis (n = 23 (42%)). In one patient complete
tumour resection with negative margins could be
achieved in case of tumour-associated duodenal bleeding
but new peritoneal and liver metastases were detected
(classified as R2-resection).
Among the patients amenable to secondary resection,
tumour-free resection margins were achieved in 39,2%
(R0), microscopically positive resection margins were
diagnosed in 41,2% (R1), incomplete resection with
macroscopically positive resection margins in 11,8% (R2)
Figure 1 CT scan of a female patient before (A) and after (C) neoadjuvant CRT showing a partial remission of the pancreatic tumour.
Dose distribution of the applied treatment plan (B).
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7,8% (Rx).
Influence of resection status on overall survival (OS)
Median OS of all patients was 12.3 months (95%-CI:
10.8-13.7 months, SD = 0.73). OS was 82% at 6 months,
46% at 1 and 9% at 2 years (Figure 2).
Secondary resectability was associated with better OS
(p = 0.004; Figure 3). Median OS in non-resected
patients was 11.9 months (95%-CI: 10.5-13.3 months,
SD = 0.69), and after secondary resection was at a med-
ian of 14.4 months (95%-CI: 10.4-18.4 months, SD =
2.1) (Figure 3).
R0-resected patients had a median OS of 22.1 months
(95%-CI: 10.7-33.5 months, SD = 5.8), 15.6 months (95%-
CI: 8.9-22.3 months, SD = 3.4) in case of R1-resection
and 10.3 months (95%-CI: 7.0-13.6 months, SD = 1.7) in
R2-resected patients (Figure 4). In the four cases of
pathological not definable resection margins (Rx), median
OS was comparatively worse with 4.3 months (95%-CI:
2.8-5.9 months, SD 0.79). OS differed significantly
between R0-resected patients and unresected patients (p
= 0.003) and between R1-resected patients and those not
amenable to secondary resection (p = 0.029).
Patterns of disease progression and disease-free survival
During follow-up patients underwent CT or MRI scans
regularly and progression of disease was detected in 105
patients, of which local tumour progression was seen in
36 (34%) and distant metastasis in 89 patients (68%).
Both local and systemic progression was seen in 20
patients (19%). Main site of systemic disease progression
was the liver (52%) and the peritoneum (36%). As
described above a total of 23 metastases were discovered
during explorative laparotomy.
Median time to disease progression (DFS) was 8.1
months (95%-CI: 6.6-9.6 months, SD = 0.7). There was
Figure 2 Kaplan-Meier estimate of overall survival (OS) of all
patients.
Figure 3 Kaplan-Meier estimates comparing survival of
resected patients and non-resected patients after neoadjuvant
CRT.
Figure 4 Kaplan-Meier estimate for overall survival (OS) of
patients according to resection status.
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unresected patients with 10.8 and 5.9 months respec-
tively (p < 0.001) (Figure 5).
Toxicity of chemoradiation
Radiation side effects observed were mild in all patients
and included nausea, fatigue and diarrhoea. Haematolo-
gical toxicity attributed to GEM chemotherapy was pri-
marily CTCAE (version 4.03) grade I-III and consisted
of thrombocytopenia or neutropenia. As previously
described, in one patient duodenal bleeding appeared
after CRT due to tumour infiltration or as a conse-
quence of therapy. The patient underwent a radical duo-
denopancreatectomy with tumour-free resection
margins. No further grade IV or V toxicities were
observed. Notably in 63% of all patients administration
of GEM had to be interrupted for more than one week
mainly because of haematological toxicity I°-III°. Cholan-
gitis was recorded in 6 patients during CRT and was
clinically manageable with antibiotic and supportive
treatment. Skin reactions after GEM application were
seen in 3 patients; in one of these patients systemic
therapy was discontinued. Gemcitabine-induced pneu-
monitis was diagnosed in one patient. One patient died
13 days after the end of radiotherapy and thus before
the planned restaging.
Discussion
Neoadjuvant chemoradiation can lead to secondary
resectability in patients with LAPC, and patients amen-
able to resection profit substantially with respect to
overall survival. In our group of 215 patients, secondary
resection was possible in a high percentage of all
patients, and overall survival was increased significantly
in these operated patients from a median of 11.9
months to a maximum of 22.1 months in completely
resected patients. This fact underlines the high impor-
tance of a margin-free resection in pancreatic cancer
patients to improve survival.
In the literature, it is reported that about 10-20% of all
patients can be treated with a surgical resection directly
after diagnosis [10,23]. However, depending on the
experience of the surgical center, these numbers may
vary substantially. Higher patient load and specialization
on pancreatic cancer surgery are associated with higher
resectability rates and lower perioperative mortality
[24,25], and thus more patients are primarily classified
as resectable. This means, on the contrary, that patients
with locally advanced disease referred to neoadjuvant
chemoradiation for downsizing may represent a sub-
group of patients in such a center associated with very
large tumours or other negative prognostic factors.
Combined radiation and chemotherapy (CRT) is cer-
tainly the most self-evident strategy for tumour down-
sizing, and the efficacy of this approach has been
confirmed for many other tumours in gastrointestinal
oncology [3-5]. However, for pancreatic cancer, clinical
data have failed so far to indicate which patients may
benefit from a neoadjuvant approach. In recent analyses
there is growing evidence that supports this therapeutic
approach to obtain a higher rate of secondary resectabil-
ity and prolonged survival [18,19,26].
Gillen et al. have recently summarized 111 studies
including 4394 patients that underwent preoperative/
neoadjuvant treatments in case of unresectable, resect-
able and borderline resectable pancreatic cancer [18].
The authors demonstrated that in patients initially
resectable, neoadjuvant treatment does not impact
resectability, resection status or outcome compared to
initial resection and adjuvant treatment. However, in the
group of locally advanced and unresectable patients,
about 1/3 of the tumours become resectable during the
course of treatment. OS was increased from 9.5 months
(range 6-12 months) in non-resected patients to 20.5
months (range 9-62 months) in patients undergoing sec-
ondary resection.
According to Gillen and colleagues, resectability cri-
teria varied substantially within the included studies
[18]: A minority of studies focussed on the NCCN
guidelines for resectability [27]. The majority of studies
did not report any detailed information on their resect-
ability criteria. This information clearly underlines that
decision for resection and classification of patients as
locally inoperable depends on the treating center and
their expertise and experience in the field. Moreover,
Figure 5 Kaplan-Meier estimate for disease-free survival (DFS)
of resected and unresected patients.
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outcome as well as side effects in pancreatic cancer
treatment [28-35].
In our analysis, median OS after secondary resection
with tumour-free resection margins was 22.1 months,
which is significantly higher than OS in the group of
non-resected patients (11.9 months); however, compared
to similar studies reporting outcome after neoadjuvant
treatment [19], survival rates are somewhat lower. Con-
cerning this fact it has to be considered that only
patients with unresectable tumours were included in
this study. Due to the high throughput of pancreatic
cancer patients at our center, it is most likely that
patients referred to neoadjuvant treatment are the most
difficult candidates for curative resection, associated
with negative prognostic factors.
Despite this fact, our data clearly show that over one
fourth of the patients are qualified for secondary resec-
tion, and those patients significantly benefit with respect
to OS and DFS. Our results are in accordance with pub-
lished data on resection rates after neoadjuvant CRT
which are reported to lie between 10-20% (recently
reviewed by [36]).
According to current literature one of the main sites
of R1 resection in pancreatic head cancer is the meso-
pancreatic region [37]. Median survival after R1-resec-
tion was 15.6 and 5.6 months in R2- and Rx-resected
patients (p < 0.05). Importance of resection status was
also observed in DFS of different patient groups. While
median DFS for all patients was 8.1 months, resected
patients had a significant later onset of disease progres-
sion with 10.8 months.
Nevertheless, distant metast a s i si ss t i l lo b s e r v e di na
high percentage of pancreatic cancer patients. A recent
mono-institutional analysis reports that a majority of
145 curatively resected patients developed distant metas-
tases during follow-up predominantly in the liver or
peritoneum rather than a local relapse [38].
Also in our analysis systemic disease progression was
more frequent than local progression. Main sites of distant
metastasis were the liver (52%) and the peritoneum (36%).
A diagnostic biopsy was not achievable in all of the
analyzed patients but nevertheless treatment as
described above was initiated according to local guide-
lines. In these cases, characteristic CT or MRI morpho-
logical findings and elevated CA 19-9 levels in the blood
serum were required for treatment initiation.
Pancreatic cancer is still having a dismal prognosis
and only a minority of patients can undergo curative
resection at time of diagnosis. Neoadjuvant GEM-based
CRT for LAPC without evidence of distant metastases
can lead to a high rate of second resectability resulting
in long-term survival and disease-free survival.
Nevertheless disease progression is seen in a vast major-
ity of patients, especially occurrence of distant metas-
tases still remains the predominant site of disease
progression.
In conclusion, this work confirms the value of neoad-
juvant treatment in locally advanced pancreatic cancer
observed in a very large group of homogeneously treated
patients. Future clinical trials will prove if a neoadjuvant
systemic therapy (with gemcitabine) followed by concur-
rent CRT and subsequent resection will help to identify
patients that benefit from an intensified therapy.
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